Millennium Pharmaceuticals: more Velcade ventures

... Millennium Pharmaceuticals: more Velcade ventures - Pharmaceutical Business Review Wednesday, 8th March 2006 Search Pharmaceutical Business Review for: HOME Latest News Industry Metrics Issue Drill-down Newsletter Sign-Up ANALYSIS CENTERS Drug Delivery Epidemiology Generics Medical Devices Strategic Issues Therapeutic Areas FREE RESEARCH Find a Company Events & Webinars INTELLIGENCE STORE Latest Research Browse by Industry Best Sellers Industry Profiles ABOUT THIS SITE Syndication (XML) Advertise with us Privacy Customer Service Contact us Millennium Pharmaceuticals: more Velcade ventures 7th March 2006 By Staff Writer Millennium Pharmaceuticals has initiated a phase II lung cancer trial with Velcade plus pemetrexed.

Millennium Pharmaceuticals and Johnson & Johnson have initiated a phase II trial of Velcade in combination with pemetrexed in non small lung cancer (NSCLC).

Although Velcade's performance in this indication has been impressive so far, the NSCLC market is becoming increasingly crowded with targeted therapies, which could hinder Velcade's uptake.

Advertisement The trial will study the effects of Velcade (bortezomib) in patients with NSCLC who have failed prior chemotherapy.

It aims to recruit 135 patients who will be randomized to receive either Velcade and pemetrexed (marketed as Read more...

1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 | 61 | 62 | 63 | 64 | 65 | 66 | 67 | 68 | 69 | 70 | 71 | 72 | 73 | 74 | 75 | 76 | 77 | 78 | 79 | 80 | 81 | 82 | 83 | 84 | 85 | 86 | 87 | 88 | 89 | 90 | 91 | 92 | 93 | 94 | 95 | 96 | 97 | 98 | 99 | All news